Why Drug Safety Should Not Take a Back Seat to Efficacy

1. PirmohamedMJamesSMeakinSGreenCScottAK 2004 Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. BMJ 329 15 19

2. StromB 2004 Potential for conflict of interest in the evaluation of suspected adverse drug reactions. JAMA 292 2643 2646

3. CarpenterDZuckerEJAvornJ 2008 Drug-review deadlines and safety problems. N Engl J Med 358 1354 1361

4. GolderSLokeYKBlandM 2011 Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: Methodological overview. PLoS Med 8 5 e1001026 doi:10.1371/journal.pmed.1001026

5. McGettiganPHenryD 2011 Cardiovascular Risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 8 9 e1001098 doi:10.1371/journal.pmed.1001098

6. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Home page. Available: http://www.encepp.eu/

7. SchneeweissSAvornJ 2011 Postmarketing studies of drug safety. BMJ 342 d342

8. LaineCHortonRDeAngelisCDDrazenJMFrizelleFA 2007 Clinical trial registration —⁠ Looking back and moving ahead. N Engl J Med 356 2734 2736

9. CONSORT: Transparent Reporting of Trials. Home page. Available: http://www.consort-statement.org/